The Apex Times
Above the Noise
Business Wire
BusinessEstee Lauder and Nike take different paths in their latest leadership-led turnaround attempts, with results divergingThe Apex TimesBusinessNvidia vs. Broadcom: Investors Focus on a “Core” Risk Hiding in Earnings NarrativesThe Apex TimesBusinessSalesforce’s results shift the AI-cannibalization debate as investors look back at enterprise software demandThe Apex TimesBusinessApple expands Emergency SOS Live Video to Brazil, marking the feature’s first rollout outside the U.S.The Apex TimesBusinessNetflix previews “Real Men 2,” with the return of core cast for its second seasonThe Apex TimesBusinessMicrosoft’s stock has lagged broader software services peers over the past year, but analysts remain bullishThe Apex TimesBusinessSuperX wins its first Australian order for 128 NVIDIA B300 AI server units, via EzisightThe Apex TimesBusinessExxonMobil investors weigh a valuation gap even as Mozambique LNG plans provide a potential floorThe Apex TimesBusinessWalmart and Costco face the same question for dividend-focused investors: which holds up better through late 2026?The Apex TimesBusinessMarvell slides about 7% after Google AI timing disappointment; Intel also slips while NVIDIA holds steadierThe Apex TimesBusinessMeta investors weigh a rebound thesis after steep selloff, with a bull case targeting 50% upsideThe Apex TimesBusinessMeta Agrees to Settle Claims From 29 States for Up to $17 Billion, Following Political Push From Bernie SandersThe Apex TimesBusinessEstee Lauder and Nike take different paths in their latest leadership-led turnaround attempts, with results divergingThe Apex TimesBusinessNvidia vs. Broadcom: Investors Focus on a “Core” Risk Hiding in Earnings NarrativesThe Apex TimesBusinessSalesforce’s results shift the AI-cannibalization debate as investors look back at enterprise software demandThe Apex TimesBusinessApple expands Emergency SOS Live Video to Brazil, marking the feature’s first rollout outside the U.S.The Apex TimesBusinessNetflix previews “Real Men 2,” with the return of core cast for its second seasonThe Apex TimesBusinessMicrosoft’s stock has lagged broader software services peers over the past year, but analysts remain bullishThe Apex TimesBusinessSuperX wins its first Australian order for 128 NVIDIA B300 AI server units, via EzisightThe Apex TimesBusinessExxonMobil investors weigh a valuation gap even as Mozambique LNG plans provide a potential floorThe Apex TimesBusinessWalmart and Costco face the same question for dividend-focused investors: which holds up better through late 2026?The Apex TimesBusinessMarvell slides about 7% after Google AI timing disappointment; Intel also slips while NVIDIA holds steadierThe Apex TimesBusinessMeta investors weigh a rebound thesis after steep selloff, with a bull case targeting 50% upsideThe Apex TimesBusinessMeta Agrees to Settle Claims From 29 States for Up to $17 Billion, Following Political Push From Bernie SandersThe Apex TimesBusinessEstee Lauder and Nike take different paths in their latest leadership-led turnaround attempts, with results divergingThe Apex TimesBusinessNvidia vs. Broadcom: Investors Focus on a “Core” Risk Hiding in Earnings NarrativesThe Apex TimesBusinessSalesforce’s results shift the AI-cannibalization debate as investors look back at enterprise software demandThe Apex TimesBusinessApple expands Emergency SOS Live Video to Brazil, marking the feature’s first rollout outside the U.S.The Apex TimesBusinessNetflix previews “Real Men 2,” with the return of core cast for its second seasonThe Apex TimesBusinessMicrosoft’s stock has lagged broader software services peers over the past year, but analysts remain bullishThe Apex TimesBusinessSuperX wins its first Australian order for 128 NVIDIA B300 AI server units, via EzisightThe Apex TimesBusinessExxonMobil investors weigh a valuation gap even as Mozambique LNG plans provide a potential floorThe Apex TimesBusinessWalmart and Costco face the same question for dividend-focused investors: which holds up better through late 2026?The Apex TimesBusinessMarvell slides about 7% after Google AI timing disappointment; Intel also slips while NVIDIA holds steadierThe Apex TimesBusinessMeta investors weigh a rebound thesis after steep selloff, with a bull case targeting 50% upsideThe Apex TimesBusinessMeta Agrees to Settle Claims From 29 States for Up to $17 Billion, Following Political Push From Bernie SandersThe Apex TimesBusinessEstee Lauder and Nike take different paths in their latest leadership-led turnaround attempts, with results divergingThe Apex TimesBusinessNvidia vs. Broadcom: Investors Focus on a “Core” Risk Hiding in Earnings NarrativesThe Apex TimesBusinessSalesforce’s results shift the AI-cannibalization debate as investors look back at enterprise software demandThe Apex TimesBusinessApple expands Emergency SOS Live Video to Brazil, marking the feature’s first rollout outside the U.S.The Apex TimesBusinessNetflix previews “Real Men 2,” with the return of core cast for its second seasonThe Apex TimesBusinessMicrosoft’s stock has lagged broader software services peers over the past year, but analysts remain bullishThe Apex TimesBusinessSuperX wins its first Australian order for 128 NVIDIA B300 AI server units, via EzisightThe Apex TimesBusinessExxonMobil investors weigh a valuation gap even as Mozambique LNG plans provide a potential floorThe Apex TimesBusinessWalmart and Costco face the same question for dividend-focused investors: which holds up better through late 2026?The Apex TimesBusinessMarvell slides about 7% after Google AI timing disappointment; Intel also slips while NVIDIA holds steadierThe Apex TimesBusinessMeta investors weigh a rebound thesis after steep selloff, with a bull case targeting 50% upsideThe Apex TimesBusinessMeta Agrees to Settle Claims From 29 States for Up to $17 Billion, Following Political Push From Bernie SandersThe Apex Times
Back to front
FDA approval expands Eli Lilly’s Mounjaro label to reduce cardiovascular risk in type 2 diabetes
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 7:16 AM EDT

FDA approval expands Eli Lilly’s Mounjaro label to reduce cardiovascular risk in type 2 diabetes

Eli Lilly said the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to lower the risk of major cardiovascular events in adults with type 2 diabetes, extending the obesity-and-diabetes drug’s role beyond glucose control.

2 min readEditor-approved Apex article

Eli Lilly and Co. said the U.S. Food and Drug Administration has approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. The company made the announcement in a market update published on Aug. 28, following the agency’s action on the expanded use of the drug.

Mounjaro is described in the announcement as a dual GIP and GLP-1 hormone receptor agonist. In plain terms, it is designed to mimic two gut-incretin indicates involved in appetite, insulin release, and other metabolic processes. The additional FDA indication ties those mechanisms to cardiovascular outcomes rather than only blood sugar management.

The new labeling is focused on lowering the risk of “major adverse” cardiovascular events in the relevant patient population, according to the same report. While the update does not spell out event definitions or outcome thresholds, it frames the approval as an outcome-based step for people living with type 2 diabetes who are at higher risk of cardiovascular complications.

For Lilly, the approval comes as GLP-1 and related therapies remain among the most scrutinized and commercially important drug classes in the U.S. market. Cardiovascular risk reduction has become a key benchmark for clinicians and payers when considering diabetes medicines, particularly as treatment decisions increasingly weigh long-term event outcomes alongside A1C lowering and weight effects.

The approval also reinforces how Lilly is positioning Mounjaro within its broader portfolio. The company’s dual-incretin approach differentiates Mounjaro from single-pathway GLP-1 therapies, and an FDA label tied to cardiovascular risk provides additional justification for use in patients where clinicians are aiming to reduce heart-related endpoints.

Still, the report as published does not provide several details that investors and clinicians typically look for in an FDA label update, including the specific trial data that supported the decision, the precise list of adjudicated endpoints, the subgroup analyses, and any limitations around patient selection. It also does not clarify how quickly the expanded indication will be incorporated into prescribing practices or reimbursement coverage.

Market reaction to label expansions can be sensitive to how broad the indication is and whether it aligns with the populations clinicians already treat. Here, the announcement is clear that the approval is for adults with type 2 diabetes and is aimed at cardiovascular risk reduction, but it leaves open the practical questions of which patients will be prioritized and how payers will respond.

Why It Matters

  • Cardiovascular-risk reduction is a major factor shaping how diabetes medications are selected and reimbursed in the U.S.
  • An FDA expansion tied to heart outcomes can broaden the addressable market for Mounjaro among patients with type 2 diabetes at elevated cardiovascular risk.
  • The approval also strengthens the clinical narrative for dual-incretin mechanisms versus narrower, single-pathway approaches.
  • Investors will likely watch whether payers, formularies, and prescribing patterns shift as the expanded indication is implemented.

Sources

Key Facts

  • Eli Lilly said the FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes.
  • The reported expanded use is described as lowering the risk of major adverse cardiovascular events.
  • Mounjaro is characterized as a dual GIP and GLP-1 hormone receptor agonist.
  • Lilly made the announcement on Aug. 28, 2026, through a market update carried by Yahoo Finance.
  • The available report does not detail trial endpoints, effect sizes, or any label limitations.

Healthcare Related